Document is current
Any future updates will be listed below
-
Authors
Wang, Chris Kedong
Nelepcu, Irina
Hui, Desmond
Oo, Htoo Zarni
Truong, Sarah
Zhao, Sarah
Tahiry, Zakir
Esfandnia, Shaghayegh
Ghaidi, Fariba
Adomat, Hans
Dagil, Robert
Gustavsson, Tobias
Choudhary, Swati
Salanti, Ali
Sorensen, Poul H.
Al Nakouzi, Nader
Daugaard, Mads
-
Funding
Funding for this research was provided by:
St. Baldrick’s Foundation/American Association for Cancer Research/Stand Up to Cancer Pediatric Dream Team (SU2C-AACR-DT-27-17)
Canadian Institutes of Health Research (PJT-153092)
NIH Prostate Cancer (1016339)
NIH Prostate Cancer (223493)
NIH Prostate Cancer (5P50 CA097186-17)
The Novo Nordisk Foundation (NNF19OC0058387)
Prostate Cancer Canada (RS2014-02)
MITACS (IT06057)
- License Information
-
More Information
Article History
Received: 10 July 2021
Accepted: 4 February 2022
First Online: 23 February 2022
Competing interests
: MD, AS, and PHS are co-founders of, and shareholders in VAR2 Pharmaceuticals ( ) and VarCT Diagnostics ( ). NAN, RD, TG, and SC are partially employed in VAR2 Pharmaceuticals. VAR2 Pharmaceuticals and VarCT Diagnostics are biotechnology companies that specialize in therapeutic and diagnostic development of the VAR2CSA technology. Rest of the authors declare no competing interests.
